AQST - Aquestive Therapeutics, Inc.
NEXT EARNINGS:
Mar 4, 2026
(in 7 days)
EPS Est: $-0.13
|
Rev Est: $13.3M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$10.00
DETAILS
HIGH:
$12.00
LOW:
$6.00
MEDIAN:
$12.00
CONSENSUS:
$10.00
UPSIDE:
144.50%
Market Cap:
406.16M
Volume:
2,437,241
Avg Volume:
4,895,760
52 Week Range:
2.12-7.55
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Beta:
1.66
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
142
IPO Date:
2018-07-25
EPS (TTM):
-0.51
P/E Ratio:
-7.00
Revenue (TTM):
57.56M
Total Assets:
101.42M
Total Debt:
38.00M
Cash & Equiv:
71.55M
Rev Growth (5Y):
1.8%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-33.1%
Debt/Equity:
-0.63
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $-0.14 | $-0.11 | -27.3% | $12.8M | $12.9M | -1.1% |
| 2025-08-11 | $-0.14 | $-0.18 | +22.2% | $10.0M | $12.2M | -18.0% |
| 2025-05-12 | $-0.24 | $-0.17 | -41.2% | $8.7M | $12.2M | -28.7% |
| 2025-03-05 | $-0.19 | $-0.14 | -35.7% | $11.9M | $13.1M | -9.5% |
| 2024-11-04 | $-0.13 | $-0.12 | -8.3% | $13.5M | $13.1M | +3.2% |
| 2024-08-06 | $-0.03 | $-0.11 | +72.7% | $20.1M | $12.4M | +62.4% |
| 2024-05-07 | $-0.17 | $-0.09 | -88.9% | $12.1M | $12.3M | -1.7% |
| 2024-03-05 | $-0.12 | $-0.08 | -50.0% | $13.2M | $11.6M | +13.6% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.56M | 50.58M | 47.68M | 50.83M | 45.85M | 52.61M | 67.43M | 66.92M | 51.78M |
| Net Income | (44.14M) | (7.87M) | (54.41M) | (70.54M) | (55.78M) | (66.25M) | (61.38M) | (8.94M) | (9.60M) |
| EPS | -0.51 | -0.13 | -1.12 | -1.85 | -1.66 | -2.87 | -2.96 | -0.45 | -0.39 |
| Total Assets | 101.42M | 57.42M | 57.07M | 61.99M | 62.88M | 78.48M | 86.85M | 43.12M | 39.39M |
| Total Debt | 38.00M | 33.32M | 57.49M | 56.42M | 40.48M | 60.34M | 47.20M | 45.51M | 38.65M |
| Cash & Equivalents | 71.55M | 23.87M | 27.27M | 28.02M | 31.81M | 49.33M | 60.60M | 17.38M | 9.21M |
| Operating Cash Flow | (35.76M) | (6.38M) | (9.79M) | (32.98M) | (45.46M) | (60.21M) | (12.99M) | 5.82M | (8.18M) |
| Free Cash Flow | (35.92M) | (7.38M) | (12.31M) | (33.89M) | (45.98M) | (60.87M) | (14.81M) | 3.76M | (9.15M) |
| FCF per Share | -0.41 | -0.12 | -0.25 | -0.89 | -1.37 | -2.40 | -0.71 | 0.19 | -0.37 |
| Book Value | (60.16M) | (106.49M) | (118.55M) | (82.13M) | (48.50M) | (6.12M) | 10.08M | (26.50M) | (17.58M) |
| Cash & ST Investments | 71.55M | 23.87M | 27.27M | 28.02M | 31.81M | 49.33M | 60.60M | 17.38M | 9.21M |
| ROC Equity | N/A | N/A | N/A | N/A | N/A | N/A | -6.09 | N/A | N/A |